Palatin Technologies, Inc. (PTN)
Oxford Ledge is still expanding full research coverage of PTN. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Palatin develops receptor-specific melanocortin-based medicines for obesity, inflammatory diseases, and other conditions, partnering with industry leaders for commercialization.
SEC filings
- DEF 14A Proxy statement for shareholder vote 2026-06-25
- 8-K Delisting / transfer of listing; Regulation FD disclosure; Financial statements and exhibits 2026-05-18
- 10-Q Quarterly financial report (unaudited) 2026-05-13
- 10-Q Quarterly financial report (unaudited) 2026-02-17
- 10-Q Quarterly financial report (unaudited) 2025-11-14
Source: SEC EDGAR.
- Open PTN in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.